Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.
Mizutani
K
K
Tamada
Y
Y
Hara
K
K
Tsuzuki
T
T
Saeki
H
H
Tamaki
K
K
Matsumoto
Y
Y
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D018223:Dermatofibrosarcoma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008161:Lumbosacral Region; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate